Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment

Overview

This phase II trial studies the side effects of radiation therapy (hypofractionated proton beam therapy or IMRT) for the treatment of prostate cancer that has come back (recurrent) or that has spread to a limited number of sites (oligometastatic) following primary localized treatment. Hypofractionated proton beam radiation therapy delivers smaller doses of radiation therapy over time and may kill more tumor cells and have fewer side effects. IMRT uses high energy x-rays to kill tumor cells and shrink tumors. This trial is being done to find out if a shorter course of radiation therapy is better with fewer side effects for patients with recurrent prostate cancer.

Full Title of Study: “A Randomized, Parallel Phase II Trial of Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer Involving Only Pelvic and/or Para-Aortic Lymph Nodes Following Primary Localized Treatment”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2024

Detailed Description

PRIMARY OBJECTIVE: I. To assess late >= grade 3 gastrointestinal (GI) and/or genitourinary (GU) toxicity of interest with the hypofractionated regimen with proton beam therapy or intensity-modulated radiation therapy (IMRT) (late defined as 3 to 24 months after protocol radiation therapy [RT]). SECONDARY OBJECTIVES: I. Late grade >= 2 GI and/or GU toxicities of interest within 24 months after the protocol RT, using the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0. II. Acute grade >= 3 GI and/or GU toxicities of interest during and within 3 months after the protocol RT, using the CTCAE v4.0. III. Compare the rates of late >= grade 3 GI and/or GU toxicity between the 2 treatment schedules. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo proton beam radiation therapy 5 days a week over 3 weeks. Patients undergo positron emission tomography (PET) scan, computed tomography (CT) scan, magnetic resonance imaging (MRI), and blood sample collection throughout the study. ARM II: Patients undergo IMRT 5 days a week over 5 weeks. Patients undergo PET scan, CT scan, MRI, and blood sample collection throughout the study. After completion of study, patients are followed up at 3-6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months.

Interventions

  • Radiation: Intensity-Modulated Radiation Therapy
    • Undergo IMRT
  • Radiation: Proton Beam Radiation Therapy
    • Undergo proton beam radiation therapy
  • Other: Quality-of-Life Assessment
    • Ancillary studies
  • Other: Questionnaire Administration
    • Ancillary studies
  • Procedure: Computed Tomography
    • Undergo CT scan
  • Procedure: Magnetic Resonance Imaging
    • Undergo MRI
  • Procedure: Biospecimen Collection
    • Undergo blood sample collection

Arms, Groups and Cohorts

  • Experimental: Arm I (proton beam radiation therapy)
    • Patients undergo proton beam radiation therapy 5 days a week over 3 weeks. Patients undergo PET scan, CT scan, MRI, and blood sample collection throughout the study.
  • Experimental: Arm II (IMRT)
    • Patients undergo IMRT 5 days a week over 5 weeks. Patients undergo PET scan, CT scan, MRI, and blood sample collection throughout the study.

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of patients who experience a late (>= 90 days after radiation therapy [RT] start date) grade 3 or higher gastrointestinal (GI) and/or genitourinary (GU) adverse event (AE)
    • Time Frame: Up to 24 months after RT
    • Toxicity will be defined as an adverse event possibly, probably, or definitely related to proton beam therapy. The proportion of grade 3 or higher GI or GU toxicities will be estimated by the number of patients with a late grade 3 or higher GI or GU toxicity divided by the total number of evaluable patients. Exact binomial 90% confidence intervals for the toxicity proportion will be calculated.

Secondary Measures

  • Incidence of acute adverse events
    • Time Frame: Up to 3 months after the completion of RT
    • The rate of >= grade 3 GI or GU acute adverse events will be estimated by the number of patients with a >= grade 3 GI or GU acute adverse event divided by the total number of evaluable patients. Exact binomial 90% confidence intervals for the true rate of >= grade 3 GI or GU acute adverse events will be calculated.
  • Incidence of late adverse events
    • Time Frame: Between 3 months and 2 years after completion of proton beam therapy
    • The rate of >= grade 2 GI or GU late adverse events will be estimated by the number of patients with a >= grade 2 GI or GU late adverse event divided by the total number of evaluable patients. Exact binomial 90% confidence intervals for the true rate of >= grade 2 GI or GU late adverse events will be calculated.
  • Proportion of grade 3 or higher GI or GU adverse events
    • Time Frame: Up to 60 months
    • The difference between the 2 treatment arm proportions will be determined and exact binomial 90% confidence intervals for the difference in grade 3 or higher GI or GU toxicity rates will be calculated.
  • Incidence of adverse events
    • Time Frame: Up to 60 months
    • All eligible patients that have initiated treatment will be considered evaluable for assessing adverse event rate(s). The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Acute and late adverse events will be summarized separately.

Participating in This Clinical Trial

Inclusion Criteria

  • Male; age >= 18 years – Histological confirmation of prostate adenocarcinoma – Recurrent prostate cancer after prior receipt of primary radiotherapy to the prostate (can also include treatment of splenic vessels [SVs] and lymph nodes [LNs]) or salvage RT to the prostate fossa (can also include prior pelvic RT) – Oligometastatic extent of disease – Recurrent disease involving lymph nodes as diagnosed with choline positron emission tomography (PET)/computed tomography (CT) or other advanced PET imaging (prostate-specific membrane antigen [PSMA] or flucyclovine) – Limited to pelvic and/or retroperitoneal/para-aortic lymph nodes – Zubrod performance score (PS) =< 1 – Signed informed consent Exclusion Criteria:

  • Bone or visceral metastases present – Lymph node metastases beyond the pelvis and/or retroperitoneum – Contraindications to RT (e.g., uncontrolled inflammatory bowel disease) – Contraindications to androgen suppression – Concurrent antineoplastic agents (chemotherapy) – Previous or concurrent malignancy other than non-melanoma skin cancer within 5 years of diagnosis of prostate cancer – Inability to start the radiation portion of the protocol treatment within 6 months after study enrollment – Medical or psychiatric conditions that preclude informed decision-making or compliance with the protocol treatment or follow-up

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mayo Clinic
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Brian J. Davis, M.D., Principal Investigator, Mayo Clinic in Rochester

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.